Terapija lijekovima kod simptoma povezanih s anksioznošću u odraslih bolesnika na palijativnoj skrbi
Referencias
References to studies excluded from this review
Centeno C, Sanz A, Cuervo MA, Ramos D, Hernansanz S, Gonzalez J, et al. Multicentre, double‐blind, randomised placebo‐controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. British Medical Journal Supportive and Palliative Care 2012;2(4):328‐33. [DOI: 10.1136/bmjspcare‐2011‐000093]
Dauchy S, Majed L, Saltel P, Reich M, Rouby P, Lopez C, et al. A randomized, double‐blind, placebo‐controlled trial of escitalopram for the treatment of emotional distress during treatment for head and neck cancer. Psycho‐Oncology 2015;24:332. [DOI: 10.1002/pon.3874]
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced‐stage cancer. Archives of General Psychiatry 2011;68(1):71‐8. [DOI: 10.1001/archgenpsychiatry.2010.116]
Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, et al. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28‐day open‐label proof‐of‐concept trial. Journal of Palliative Medicine 2013;16(8):958‐65. [DOI: 10.1089/jpm.2012.0617]
Kronish IM, Chaplin WF, Rieckmann N, Burg MM, Davidson KW. The effect of enhanced depression care on anxiety symptoms in acute coronary syndrome patients: findings from the COPES trial. Psychotherapy and Psychosomatics 2012;81(4):245‐7. [DOI: 10.1159/000332439]
Ng CG, Boks MP, Roes KC, Zainal NZ, Sulaiman AH, Tan SB, et al. Rapid response to methylphenidate as an add‐on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four‐week, randomized, double‐blinded, placebo‐controlled study. European Neuropsychopharmacology 2014;24(4):491‐8. [DOI: 10.1016/j.euroneuro.2014.01.016]
Yazici AE, Erdem P, Erdem A, Yazici K, Acar ST, Basterzi AD, et al. Efficacy and tolerability of escitalopram in depressed patients with end stage renal disease: an open placebo‐controlled study. Klinik Psikofarmakoloji Bulteni 2012;22(1):23‐30. [DOI: 10.5455/bcp.20120215011558]
References to studies awaiting assessment
Additional references
Baldwin DS, Nutt DJ, Bandelow B, Bond A, Davidson JRT, den Boer JA, et al. Evidence‐based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19:567‐96. [DOI: 10.1177/0269881105059253]
Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine 2001;2:297‐307. [PUBMED: 11438246]
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561‐71. [PUBMED: 13688369]
Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988;56:893‐7. [PUBMED: 3204199]
Bradburn N. The Structure of Psychological Well‐being. Chicago (IL): Aldine, 1969.
Breitbart W, Jacobsen PB. Psychiatric symptom management in terminal care. Clinics in Geriatric Medicine 1996;12(2):329‐47. [PUBMED: 8799351]
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. Journal of Palliative Care 1991;7(2):6‐9. [PUBMED: 1714502]
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research 1989;28:192‐213. [PUBMED: 2748771]
de Haes JCJM, Olschewski M, Fayers P, Visser MRM, Cull A, Hopwood P, et al. The Rotterdam Symptom Checklist (RSCL). A Manual. Northern Centre for Healthcare Research (NCH), University of Groningen, the Netherlands1996.
Derogatis LR, Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychological Medicine 1983;33:67‐75. [PUBMED: 6622612]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5). Arlington (VA): American Psychiatric Association, 2013.
American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Arlington (VA): American Psychological Association, 1980.
American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Arlington (VA): American Psychological Association, 1994.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington (VA): American Psychiatric Association, 2000.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Arlington (VA): American Psychiatric Association, 1987.
Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50‐5. [DOI: 10.1111/j.2044‐8341.1959.tb00467.x]
Hearn J, Higginson IJ. Development and validation of a core outcome measure for palliative care: the palliative care outcome scale. Palliative Care Core Audit Project Advisory Group. Quality in Health Care : QHC 1999;8:219‐27.
Henderson M, MacGregor E, Sykes N, Hotopf M. The use of benzodiazepines in palliative care. Palliative Medicine 2006;20(4):407‐12. [PUBMED: 16875110]
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higginson I. Audit methods: a community schedule. In: Higginson I editor(s). Clinical Audit in Palliative Care. Oxford: Radcliffe Medical Press, 1993:34‐47.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Geneva: World Health Organization2010.
Jackson KC, Lipman AG. Anxiety in palliative care patients. Journal of Pharmaceutical Care in Pain and Symptom Control 2000;7(4):23‐35.
Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respiratory Medicine 1991;85 (Suppl B):25‐31. [PUBMED: 1759018]
Khojainova N, Santiago‐Palma J, Kornick C, Breitbart W, Gonzales GR. Olanzapine in the management of cancer pain. Journal of Pain and Symptom Management 2002;23(4):346‐50. [PUBMED: 11997204]
Klein C, Lang U, Bükki J, Sittl R, Ostgathe C. Pain management and symptom‐oriented drug therapy in palliative care. Breast Care 2011;6:27‐34. [DOI: 10.1159/000324702]
Kolva E, Rosenfeld B, Pessin H, Breitbart W, Brescia R. Anxiety in terminally ill cancer patients. Journal of Pain and Symptom Management2011; Vol. 42, issue 5:691‐701. [DOI: 10.1016/j.jpainsymman.2011.01.013]
Maguire P, Faulkner A, Regnard C. Managing the anxious patient with advancing disease ‐ a flow diagram. Palliative Medicine 1993;7:239‐44. [PUBMED: 8261191]
Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis. International Journal of Geriatric Psychiatry 2001;16(Suppl 1):S71‐7. [PUBMED: 11748790]
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative‐care settings: a meta‐analysis of 94 interview‐based studies. Lancet Oncology 2011;12(2):160‐74. [DOI: 10.1016/S1470‐2045(11)70002‐X]
Moorey S, Cort E, Kapari M, Monroe B, Hansford P, Mannix K, et al. A cluster randomized controlled trial of cognitive behaviour therapy for common mental disorders in patients with advanced cancer. Psychological Medicine 2009;39(5):713‐23. [DOI: 10.1017/S0033291708004169]
National Consensus Project for Quality Palliative Care. Clinical Practice Guidelines for Quality Palliative Care, Second edition2009.
National Palliative and End of Care Partnership. Ambitions for palliative and end of life care: a national framework for local action 2015‐2020, 2015. endoflifecareambitions.org.uk/wp‐content/uploads/2015/09/Ambitions‐for‐Palliative‐and‐End‐of‐Life‐Care.pdf (accessed 11 March 2017).
National Institute for Health and Care Excellence. Care of dying adults in the last days of life. NICE guideline NG31, 2015. www.nice.org.uk/guidance/ng31 (accessed 14 December 2016).
National Institute for Clinical Excellence. Improving supportive and palliative care for adults with cancer. The manual. Cancer Service Guideline (CSG4), 2004. www.nice.org.uk/guidance/csg4 (accessed 14 December 2016).
National Institute for Health and Care Excellence. End of life care for adults. Quality standard (QS13), 2011. www.nice.org.uk/guidance/qs13 (accessed 11 March 2017).
National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults. Clinical guideline (CG113), 2011. https://www.nice.org.uk/guidance/cg113/chapter/1‐guidance (accessed 14/12/16) (accessed 14 December 2016).
Noyes R, Holt CS, Massie MJ. Anxiety disorders. In: Holland JC, Breitbart W editor(s). Psycho‐oncology. New York (NY): Oxford University Press, 1998:548‐63.
Nübling G, Allmendinger S, Lorenzl S. Drug therapy of anxiety and fear in palliative care patients with cancer or other illnesses: a systematic review. Schmerz (Berlin, Germany) 2012;26(5):537‐49. [DOI: 10.1007/s00482‐012‐1241‐6]
Payne D. Cognitive Factors in Breakthrough Pain [PhD dissertation]. Louisville (KY): University of Louisville, 1995.
Pollock V, Cho DW, Reker D, Volavka J. Profile of Mood States: the factors and their physiological correlates. Journal of Nervous and Mental Disease 1979;167(10):612‐4. [PUBMED: 226658]
Robins LN, Helzer JE, Croughan J, Ratcliff KS. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Archives of General Psychiatry 1981;38(4):381‐9. [PUBMED: 6260053]
Roth AJ, Massie MJ. Anxiety and its management in advanced cancer. Current Opinion in Supportive and Palliative Care 2007;1(1):50‐6. [DOI: 10.1097/SPC.0b013e32813aeb23]
Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:697‐702. [DOI: 10.1136/bmj.c332]
Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD‐10 criteria. Journal of Psychosomatic Research 2000;48:555‐60. [PUBMED: 11033374]
Spencer R, Nilsson M, Wright A, Pirl W, Prigerson H. Anxiety disorders in advanced cancer patients: correlates and predictors of end‐of‐life outcomes. Cancer 2010;116(7):1810‐9. [DOI: 10.1002/cncr.24954]
Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State‐Trait Anxiety Inventory. Palo Alto (CA): Consulting Psychologists Press, 1983.
Thielking PD. Cancer pain and anxiety. Current Pain and Headache Reports 2003;7:249‐61.
Traeger L, Greer JA, Fernandez‐Robles C, Temel JS, Pirl WF. Evidence‐based treatment of anxiety in patients with cancer. Journal of Clinical Oncology 2012;30:1197‐205. [DOI: 10.1200/JCO.2011.39.5632]
Wilson KG, Chochinov HM, Skirko MG, Allard P, Chary S, Gagnon PR, et al. Depression and anxiety disorders in palliative cancer care. Journal of Pain and Symptom Management 2007;33(2):118‐29. [DOI: 10.1016/j.jpainsymman.2006.07.016]
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983;67(6):361‐70. [PUBMED: 6880820]
References to other published versions of this review
Candy B, Jackson KC, Jones L, Tookman A, King M. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI: 10.1002/14651858.CD004596.pub2]
Jackson KC, Lipman AG. Drug therapy for anxiety in adult palliative care patients. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004596]
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Not an RCT. | |
| Not the patient population of interest. | |
| Not an RCT | |
| Not the patient population of interest. | |
| Study discontinued. | |
| Not the patient population of interest. | |
| Not an RCT. | |
| Not an RCT. | |
| Not the patient population of interest. | |
| Not an RCT. | |
| Not the patient population of interest. | |
| Not the patient population of interest. | |
| Not the patient population of interest. | |
| Not the patient population of interest. | |
| Not the patient population of interest. | |
| Not the patient population of interest. |
RCT: randomised controlled trial.
Characteristics of studies awaiting assessment [ordered by study ID]
Ir a:
| Methods | Randomised, double‐blind, double‐dummy placebo‐controlled pilot study. |
| Participants | 30 participants with severe respiratory disease. |
| Interventions | Lorazepam tablets 0.5 mg twice daily with dummy nasal spray up to 4 times daily. Midazolam 400 mg intranasal 2 sprays up to 4 times daily with placebo tablets. |
| Outcomes | Borg score, St Georges Respiratory Questionnaire, Hospital Anxiety and Depression scores, Nottingham Activities of Daily Living score. |
| Notes | Contacted author by e‐mail in July and August 2016 to ask for further details but no response received. |
| Methods | Intervention study. |
| Participants | People with chronic obstructive pulmonary disease. |
| Interventions | Paroxetine 20 mg daily as oral capsule for 4 months. Placebo pill as oral capsule for 4 months. Capsules identical in appearance. |
| Outcomes | Anxiety as measured by Beck Anxiety Inventory, quality of life as assessed by Chronic Respiratory Questionnaire (CRQ). |
| Notes | Contacted author by e‐mail September 2016 to ask for further details but no response received. |
Figuras y tablas -
Figure 1
Study flow diagram.
